220 related articles for article (PubMed ID: 352510)
1. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
Ferrans VJ
Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
[TBL] [Abstract][Full Text] [Related]
2. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow MR; Billingham ME; Mason JW; Daniels JR
Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and prevention of doxorubicin cardiomyopathy.
Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham ME; Mason JW; Bristow MR; Daniels JR
Cancer Treat Rep; 1978 Jun; 62(6):865-72. PubMed ID: 667860
[TBL] [Abstract][Full Text] [Related]
5. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
6. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy.
Benjamin RS; Mason JW; Billingham ME
Cancer Treat Rep; 1978 Jun; 62(6):935-9. PubMed ID: 667871
[No Abstract] [Full Text] [Related]
7. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.
Jones RL; Miles DW
Lancet Oncol; 2005 Feb; 6(2):67. PubMed ID: 15683815
[No Abstract] [Full Text] [Related]
8. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.
Mettler FP; Young DM; Ward JM
Cancer Res; 1977 Aug; 37(8 Pt 1):2705-13. PubMed ID: 872096
[No Abstract] [Full Text] [Related]
9. [Cardiotoxicity of anthracyclines. Apropos of 12 pediatric cases].
Favrot MC; Pouyau G; Souillet G; Philip T; Bozzio A; Philippe N
Pediatrie; 1981 Sep; 36(6):437-50. PubMed ID: 6947199
[No Abstract] [Full Text] [Related]
10. Role of mtDNA lesions in anthracycline cardiotoxicity.
Lebrecht D; Walker UA
Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
[TBL] [Abstract][Full Text] [Related]
11. Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy.
Singer JW; Narahara KA; Ritchie JL; Hamilton GW; Kennedy JW
Cancer Treat Rep; 1978 Jun; 62(6):945-8. PubMed ID: 667873
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
13. [Cardiotoxicity of anthracyclines].
Laurent S; Colbert N; Izrael V; Motte G
Ann Med Interne (Paris); 1984; 135(6):464-72. PubMed ID: 6391323
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB
Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
[TBL] [Abstract][Full Text] [Related]
16. Early alterations of the cardiac muscle cells in isoproterenol-induced necrosis.
Csapó Z; Dusek J; Rona G
Arch Pathol; 1972 Apr; 93(4):356-65. PubMed ID: 5017287
[No Abstract] [Full Text] [Related]
17. Decreased sensitivity of neonatal rabbit sarcoplasmic reticulum to anthracycline cardiotoxicity.
Burke BE; Mushlin PS; Cusack BJ; Olson SJ; Gambliel HA; Olson RD
Cardiovasc Toxicol; 2002; 2(1):41-51. PubMed ID: 12189279
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.
Rahman A; More N; Schein PS
Cancer Res; 1982 May; 42(5):1817-25. PubMed ID: 7066898
[TBL] [Abstract][Full Text] [Related]
19. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.
Tokarska-Schlattner M; Zaugg M; Zuppinger C; Wallimann T; Schlattner U
J Mol Cell Cardiol; 2006 Sep; 41(3):389-405. PubMed ID: 16879835
[TBL] [Abstract][Full Text] [Related]
20. Sarcolemmal alterations in cardiac hypertrophy and degeneration.
Ferrans VJ; Buja LM; Maron BJ
Recent Adv Stud Cardiac Struct Metab; 1976; 9():395-419. PubMed ID: 130664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
